Purchase this article with an account.
H. Mochimaru, E. Takahashi, K. Tsubota, H. Saya, S. Ishida; Involvement of Hyarulonan With Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5883. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate a role of hyarulonan (HA), a key molecule for modulating inflammation, in the development of choroidal neovascularization (CNV).
4-methylumbelliferone (MU), an HA synthesis inhibitor, was suspended in 1% Arabic gum. The suspension was orally administered by gastric tube every day at the dose of 0.33, 1.0 or 3.0 g/kg body weight (BW). Laser photocoagulation was performed to induce CNV. One week after photocoagulation, mice were sacrificed and CNV volume was evaluated by volumetric measurements.
The development of CNV was significantly suppressed by the treatment with MU in a dose-dependent manner. MU-treated mice at the dose of 1.0 or 3.0 g/kg BW showed a significant (P<0.01) decrease in the CNV volume (308,468±163,530 µm3 for 1.0 g/kg BW, 256,696± 148,978 µm3 for 3.0 g/kg BW) compared with vehicle-treated mice (413,722±181,960 µm3).
This PDF is available to Subscribers Only